Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force
Top Cited Papers
Open Access
- 29 September 2010
- journal article
- practice guideline
- Published by Wiley in European Journal of Neurology
- Vol. 18 (1), 19-e3
- https://doi.org/10.1111/j.1468-1331.2010.03220.x
Abstract
Background: Paraneoplastic neurological syndromes (PNS) almost invariably predate detection of the malignancy. Screening for tumours is important in PNS as the tumour directly affects prognosis and treatment and should be performed as soon as possible. Objectives: An overview of the screening of tumours related to classical PNS is given. Small cell lung cancer, thymoma, breast cancer, ovarian carcinoma and teratoma and testicular tumours are described in relation to paraneoplastic limbic encephalitis, subacute sensory neuronopathy, subacute autonomic neuropathy, paraneoplastic cerebellar degeneration, paraneoplastic opsoclonus‐myoclonus, Lambert‐Eaton myasthenic syndrome (LEMS), myasthenia gravis and paraneoplastic peripheral nerve hyperexcitability. Methods: Many studies with class IV evidence were available; one study reached level III evidence. No evidence‐based recommendations grade A–C were possible, but good practice points were agreed by consensus. Recommendations: The nature of antibody, and to a lesser extent the clinical syndrome, determines the risk and type of an underlying malignancy. For screening of the thoracic region, a CT‐thorax is recommended, which if negative is followed by fluorodeoxyglucose‐positron emission tomography (FDG‐PET). Breast cancer is screened for by mammography, followed by MRI. For the pelvic region, ultrasound (US) is the investigation of first choice followed by CT. Dermatomyositis patients should have CT‐thorax/abdomen, US of the pelvic region and mammography in women, US of testes in men under 50 years and colonoscopy in men and women over 50. If primary screening is negative, repeat screening after 3–6 months and screen every 6 months up till 4 years. In LEMS, screening for 2 years is sufficient. In syndromes where only a subgroup of patients have a malignancy, tumour markers have additional value to predict a probable malignancy.Keywords
This publication has 110 references indexed in Scilit:
- Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotoniaBrain, 2010
- Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case seriesThe Lancet Neurology, 2010
- Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigenThe Lancet Neurology, 2009
- Thymomas: Review of Current Clinical PracticeThe Annals of Thoracic Surgery, 2009
- AMPA receptor antibodies in limbic encephalitis alter synaptic receptor locationAnnals of Neurology, 2009
- Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodiesThe Lancet Neurology, 2008
- Paraneoplastic syndromes of the CNSThe Lancet Neurology, 2008
- Paraneoplastic limbic encephalitis associated with potassium channel antibodies: value of anti-glial nuclear antibodies in identifying the tumourJournal of Neurology, Neurosurgery & Psychiatry, 2007
- Paraneoplastic anti–N‐methyl‐D‐aspartate receptor encephalitis associated with ovarian teratomaAnnals of Neurology, 2007
- Paraneoplastic Syndromes Affecting the Nervous SystemSeminars in Oncology, 2006